NCT03305471View on ClinicalTrials.gov

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 17, 2017

Primary Completion Date

January 3, 2019

Study Completion Date

January 3, 2019

Conditions
Hyperphosphatemia
Interventions
DRUG

DS-2330b PIB

DS-2330b as powder in bottle with stock solution (PIB)

DRUG

Placebo

Placebo matching stock solution in bottle

DRUG

Sevelamer

Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.

DRUG

DS-2330b Tablet

DS-2330b as tablet formulation

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

55114

Prism Clinical Research, Saint Paul

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research, Lakewood

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY